How Does Ki-67 Index Affect Pituitary Tumor Recurrence?

Your pathology report and surgical notes offer important clues about the likelihood of your non-functioning pituitary adenoma (NFPA) growing back, a process known as recurrence.

Note: In 2022, the World Health Organization (WHO) updated the medical term for pituitary adenomas to Pituitary Neuroendocrine Tumors (PitNETs) ^[1]. If your pathology report says “PitNET,” do not panic—it is exactly the same condition as an NFPA, just with an updated name.

Three key factors your care team looks for are the Ki-67 index, the mitotic count, and cavernous sinus invasion. Together, these markers help determine how aggressive the tumor might be and how often you will need follow-up MRI scans. It is important to remember that these pathology markers are just one piece of the puzzle; doctors also consider your age, symptoms, and the original size of your tumor when estimating recurrence risk.

The Ki-67 Labeling Index

The Ki-67 labeling index is a percentage that tells your doctor how many cells in the tumor are actively dividing and growing. Pathologists use a special stain that turns dividing cells a certain color so they can be counted under a microscope. Not all pathology reports automatically include this, so you may need to ask your doctor if it was tested.

• What is a normal range? Most pituitary tumors grow very slowly and have a low Ki-67 index, typically under 3%.
• What increases risk? If your pathology report shows a Ki-67 index of 3% or higher, the tumor is considered more likely to return or regrow ^[2]. If your number falls in a “gray area” (for example, between 3% and 10%), it generally means your risk is slightly elevated, prompting closer monitoring without causing immediate alarm. However, highly elevated levels—such as those exceeding 11% to 14%—indicate a significantly more aggressive tumor and a high risk of recurrence ^[3][4].

Mitotic Count

The mitotic count is another way pathologists measure cell division. Instead of a percentage, this is a raw count of cells (mitoses) that are visibly splitting in half when looked at under a microscope.

• How it is measured: The count is usually reported over a specific area of the tissue slide, often 2 square millimeters (2 mm²).
• What increases risk? Research shows that finding more than 3 dividing cells per 2 mm² is associated with a higher risk of the pituitary tumor recurring ^[3].

Cavernous Sinus Invasion

The cavernous sinuses are spaces located on either side of the pituitary gland that contain vital nerves and major blood vessels supplying the brain. Doctors look for signs that the tumor has pushed into this space on your pre-surgery MRI (often graded on the “Knosp scale”), though it is sometimes only discovered during the operation itself ^[5][6].

• Surgical challenges: If an NFPA invades the cavernous sinus, it becomes much more difficult for a surgeon to safely remove the entire tumor ^[5][6].
• Risk of recurrence: Because it is often too dangerous to remove tumor tissue wrapped around these critical blood vessels and nerves, small amounts of tumor tissue (often called residual tumor) are frequently left behind. As a result, tumors with cavernous sinus invasion have a higher rate of regrowth or recurrence ^[7][6].

How These Factors Affect Your Monitoring Plan

After surgery, regular imaging is crucial to catch any potential regrowth early.

• Standard monitoring: The typical surveillance schedule for an NFPA involves an initial MRI scan at 3 to 6 months post-surgery, another scan at the 1-year mark, and then annual scans for the first 5 years ^[8]. After 5 years, scans are often spaced out to 7, 10, and 15 years ^[8].
• Personalized monitoring: If your tumor has high-risk features—such as a high Ki-67 index, a high mitotic count, or residual tumor in the cavernous sinus—your doctor may recommend a more personalized, intensive surveillance strategy rather than the standard schedule ^[9][10]. Additionally, if a portion of the tumor could not be removed, your care team might discuss treatments like targeted radiation (radiosurgery, such as Gamma Knife or CyberKnife) to prevent that leftover tissue from growing ^[11].